Man­u­fac­tur­ing roundup: Mil­li­pore­Sig­ma ac­quires biore­ac­tor mak­er; Kite, Dai­ichi Sankyo change Yescar­ta agree­ment

Mil­li­pore­Sig­ma, the US and Cana­di­an life sci­ence busi­ness of Mer­ck KGaA, has ac­quired Er­bi Biosys­tems, a Mass­a­chu­setts-based de­vel­op­er of a 2 ml mi­cro-biore­ac­tor tech­nol­o­gy dubbed the Breez plat­form.

The deal aims to strength­en Mil­li­pore­Sig­ma’s po­si­tion in the pro­duc­tion of ther­a­peu­tic pro­teins al­low­ing for biore­ac­tor process­es from 2 ml to 2000 L, which can be key in “lab-scale process de­vel­op­ment,” and al­lows for more op­por­tu­ni­ties in de­vel­op­ing cell ther­a­pies. Fi­nan­cial terms of the deal were not dis­closed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER